Penamecillin
Chemical compound
- J01CE06 (WHO)
- (acetyloxy)methyl (2S,5R,6R)-3,3-dimethyl-7-oxo-6-[(phenylacetyl)amino]-4-thia-1-azabicyclo[3.2.0]heptane-2-carboxylate
- 983-85-7 Y
- 13795
- 8426255 N
- H0P1YE5581
- D05406 Y
- CHEBI:131733 N
- DTXSID10243547
- Interactive image
- CC(=O)OCOC(=O)[C@H]1C(S[C@H]2N1C(=O)[C@H]2NC(=O)CC3=CC=CC=C3)(C)C
InChI
- InChI=1S/C19H22N2O6S/c1-11(22)26-10-27-18(25)15-19(2,3)28-17-14(16(24)21(15)17)20-13(23)9-12-7-5-4-6-8-12/h4-8,14-15,17H,9-10H2,1-3H3,(H,20,23)/t14-,15+,17-/m1/s1 N
- Key:NLOOMWLTUVBWAW-HLLBOEOZSA-N N
Penamecillin, an acetoxymethyl ester of benzylpenicillin, is a prodrug processed to benzylpenicillin by esterases.[1] It has no detectable teratogenic risk to the fetus.[2]
References
- ^ Agersborg HP, Batchelor A, Cambridge GW, Rule AW (March 1966). "The pharmacology of penamecillin". British Journal of Pharmacology and Chemotherapy. 26 (3): 649–55. doi:10.1111/j.1476-5381.1966.tb01844.x. PMC 1510697. PMID 4959939.
- ^ Czeizel, A.E.; Rockenbauer, M.; SøRENSEN, H.T.; Olsen, J. (1999). "The Safety of Penicillin V: Oral Penamecillin Use During Pregnancy The Importance and Limitation of Recall Bias". Congenital Anomalies. 39 (4): 267–279. doi:10.1111/j.1741-4520.1999.tb00566.x. ISSN 0914-3505.
- v
- t
- e
(inhibit synthesis
of peptidoglycan
layer of bacterial
cell wall by binding
to and inhibiting
PBPs, a group of
D-alanyl-D-alanine
transpeptidases)
Glycopeptides Lipoglycopeptides |
|
---|---|
Lipopeptides |
|
Polymyxins |
|
Other |
|
- Inhibit PG subunit synthesis and transport: NAM synthesis inhibition (Fosfomycin)
- DADAL/AR inhibitors (Cycloserine)
- bactoprenol inhibitors (Bacitracin)
- Hydrolyze NAM-NAG
- Tyrothricin
- Isoniazid#
- Teixobactin
- #WHO-EM
- ‡Withdrawn from market
- Clinical trials:
- †Phase III
- §Never to phase III
This systemic antibiotic-related article is a stub. You can help Wikipedia by expanding it. |
- v
- t
- e